Litifilimab Demonstrates Durable Skin Clearance Through 52 Weeks in Cutaneous Lupus (DermatologyTimes) - Oct 2, 2026 - "Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin...Among participants who received litifilimab from study initiation, 27.2% achieved clear or almost clear skin at week 52, defined as a Cutaneous Lupus Activity Investigators' Global Assessment Revised (CLA-IGA-R) erythema score of 0 or 1. This represented an increase from 19.0% at week 24...Improvements were also observed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A). At week 52, 28.8% of patients achieved CLASI-70, indicating at least a 70% reduction in CLASI-A score, compared with 21.7% at week 24."
P2 data • Cutaneous Lupus Erythematosus
|